Covid-19

TARGETED DRUG DELIVERY TO TREAT COVID 19

Lifescient is developing ivermectin, an anti-parasitic medication approved as a heartworm preventative in dogs and cats to treat COVID-19. Ivermectin is also approved in humans for the treatment of some parasitic infections and external parasites such as head lice. As the world grapples with vaccine distribution, Lifescient is working on a therapeutic alternative to combat COVID- 19. Another challenge is that viruses will continue to mutate creating new strains. These new variants may require the need for new vaccines and booster shots to be administered every year. Hence, a therapeutic option will play a critical role in containing the various strains of the virus year after year. The treatment that Lifescient is developing can be rapidly distributed globally without a cold supply chain which makes it less expensive and readily deployable worldwide.

Lifescient is developing an inhalable treatment for COVID-19 that enhances pulmonary bioavailability, reduces viral load, and causes reduction in respiratory tract inflammation.

This research is supported by a grant from the United States – India Science and Technology Endowment Fund. This fund has been established between the United States and India for the purpose of promoting innovation through science and technology.

We have developed a formulation that is administered using a nebulizer. Currently, proof of concept studies are being conducted in rats. In addition to this formulation, we are also working on alternate formulations for pulmonary delivery.

Lifescient is seeking partners to fund, develop, manufacture and distribute our treatments for COVID-19. Our partners will have experience in getting product approvals in multiple markets and we will rely on these distribution networks to bring this COVID-19 treatment to market.